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community settings in the UK: A study protocol
Abstract

Introduction: Provision of palliative care is inequitable with wide variations across conditions and settings in
the UK. Lack of a standard way to classify by case complexity is one of the principle obstacles to addressing
this. We aim to develop and validate a casemix classification to support the prediction of costs of specialist
palliative care provision.
Methods and analysis: Phase I: A cohort study to determine the variables and potential classes to be
included in a casemix classification. Data are collected from clinicians in palliative care services across
inpatient hospice, hospital and community settings on: patient demographics, potential complexity/casemix
criteria and patient-level resource use. Cost predictors are derived using multivariate regression and then
incorporated into a classification using classification and regression trees. Internal validation will be conducted
by bootstrapping to quantify any optimism in the predictive performance (calibration and discrimination) of
the developed classification. Phase II: A mixed-methods cohort study across settings for external validation of
the classification developed in phase I. Patient and family caregiver data will be collected longitudinally on
demographics, potential complexity/casemix criteria and patient-level resource use. This will be triangulated
with data collected from clinicians on potential complexity/casemix criteria and patient-level resource use,
and with qualitative interviews with patients and caregivers about care provision across difference settings.
The classification will be refined on the basis of its performance in the validation data set.
Ethics and dissemination: The study has been approved by the National Health Service Health Research
Authority Research Ethics Committee. The results are expected to be disseminated in 2018 through papers for
publication in major palliative care journals; policy briefs for clinicians, commissioning leads and policy
makers; and lay summaries for patients and public. Trial registration number: ISRCTN90752212.
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Abstract
Introduction Provision of palliative care is inequitable
with wide variations across conditions and settings in the
UK. Lack of a standard way to classify by case complexity
is one of the principle obstacles to addressing this. We
aim to develop and validate a casemix classification to
support the prediction of costs of specialist palliative care
provision.
Methods and analysis Phase I: A cohort study to
determine the variables and potential classes to be
included in a casemix classification. Data are collected
from clinicians in palliative care services across inpatient
hospice, hospital and community settings on: patient
demographics, potential complexity/casemix criteria and
patient-level resource use. Cost predictors are derived
using multivariate regression and then incorporated into
a classification using classification and regression trees.
Internal validation will be conducted by bootstrapping
to quantify any optimism in the predictive performance
(calibration and discrimination) of the developed
classification. Phase II: A mixed-methods cohort study
across settings for external validation of the classification
developed in phase I. Patient and family caregiver data
will be collected longitudinally on demographics, potential
complexity/casemix criteria and patient-level resource use.
This will be triangulated with data collected from clinicians
on potential complexity/casemix criteria and patient-level
resource use, and with qualitative interviews with patients
and caregivers about care provision across difference
settings. The classification will be refined on the basis of
its performance in the validation data set.
Ethics and dissemination The study has been approved
by the National Health Service Health Research Authority
Research Ethics Committee. The results are expected to
be disseminated in 2018 through papers for publication in
major palliative care journals; policy briefs for clinicians,
commissioning leads and policy makers; and lay
summaries for patients and public.
Trial registration number ISRCTN90752212.

Strengths and limitations of this study
►► This is the first study in the UK to determine the vari-

ables and potential classes to be included in a casemix classification, which predicts costs of specialist
palliative care provision across inpatient hospice,
hospital and community settings.
►► Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis is used
to guide the reporting of this study.
►► The newly developed casemix classification in
phase I will be externally validated by using a different data set in phase II.
►► This study also promotes the implementation of outcome measures in palliative care into routine clinical
practice across different settings of care.
►► This is a UK-focused study so the casemix classification may not be directly applied to palliative care
in other countries without further investigation and
refinement.

Introduction
People with advanced and incurable illness
often suffer complex and multiple symptoms
and psychosocial concerns because of their
illness or impending death.1 2 Their families
may provide day-to-day care, as well as be
affected by their own anxieties, concerns and
potential losses. These bring increased need
for health and social care, with need being
defined as ‘the ability to benefit from health
or social care interventions’.3 Palliative care
has developed to meet the needs of these
patients and families, which addresses physical/psychological symptoms and provides
social, practical and spiritual support. The
UK ranks first in the 2015 Quality of Death
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Index—a measure of the quality of dying in 80 countries,4
and the hospice movement in the UK has provided a
model of good palliative care for those in need.
However, marked inequities exist in provision of palliative care across England. Older people and those with
non-cancer diagnoses are less likely to access specialist
palliative care.5 6 There are also major geographical variations, ranging from £186 to £6213 per person across
different primary care trusts in 2010,7 8 often resulting in a
poor match between individual needs, resources provided
to meet those needs and health outcomes achieved. With
an ageing population and increasing rates of chronic
diseases, the growing healthcare burden is overwhelmingly challenging in terms of health resource allocation
around the UK.9 With recognition of the constraints on
resources, there is support for the systematic approach
to mapping individual needs accurately and improving
the quality and efficiency of palliative care. This has been
endorsed as a high priority nationally.7
The Diagnosis-Related Group is a useful classification of healthcare needs driven by the diagnosis but is
inappropriate for palliative care, because palliative care
needs are not driven by the diagnosis but by factors such
as functional status and symptoms. Palliative care needs
a consistent method of classifying types of patients with
complexity of needs, treatment and costs, using casemix
criteria.10–12 It is necessary to identify those with more
complex palliative needs, requiring more resources. An
Australian casemix classification for palliative care was
developed in 1997, empirically tested and progressively
refined over time.13–15 The Australian casemix classification consists of classes defined by five criteria including
phase of illness, problem severity, functional status and
dependency, age and model of care, as most strongly
predictive of resource use.16 Full class definition and
categorisation are available at http://www.pcoc.org.au/.
Its implementation proved the possibility of consistently
and routinely collecting data in practice in Australia.16
However, due to variations in outcome measures collected
and palliative care provided between countries, it is
unclear whether any existing palliative care classification
can be easily applied to the UK to address unmet needs
and resolve the inequity.
This study is part of a 5-year National Institute for Health
Research-funded C-CHANGE programme (RP-PG-1210–
12015). It aims to develop and validate a casemix classification for palliative care in the UK. Specific objectives
are:
►► To determine the cost predictors of specialist palliative care, adjusting for important confounding factors
including unmet needs.
►► To develop and validate a casemix classification for
specialist palliative care.
Methods and analysis
The Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis statement17
is used to guide the reporting of this study protocol.
2

Study design and source of data
This study consists of two phases: development phase
(phase I) and validation phase (phase II). In the analysis
part of phase I, we will identify variables that predict costs
to be included in casemix classification through a cohort
study with only clinician data, and develop potential
casemix classes for palliative care which will be tested in
individual episodes of care (internal validation). In phase
II, we will prospectively validate these potential classes in
a new cohort study with patient, caregiver and clinician
data, and include qualitative interviews to ensure it works
during care transitions and longitudinally over the course
of illness (external validation).
Phase I: development phase
This is a cohort study to determine the variables and
potential classes to be included in a casemix classification, based on individual episodes of care across inpatient (hospice and hospital) and community settings. An
‘episode of care’ starts when a patient is admitted to inpatient services or begins to receive specialist palliative care
from a community-based or outpatient service, and ends
when a patient is discharged from that service or dies.
The median duration of an episode of care is expected to
be under 14 days in inpatient and at a median of 72 days
in community settings.18
Phase I was conducted between 31 July 2015 and 30
September 2016 and follow-up ended on 30 November
2016. Data were collected from clinicians through surveys,
including demographic/clinical data, episode start/
end data, patient attributes that predict palliative care
resource consumption (eg, phase of illness, functional
status and problem severity as identified in the Australian casemix classification study13 14 16), plus information
on patient-level resource use (staff activity and clinical
services) in specialist palliative care settings.
Phase II: validation phase
This phase is a mixed-methods cohort study with a concurrent nested design:19
►► Quantitative main component—prospectively collect
data from patients, caregivers and clinicians on palliative care needs, concerns, outcomes and resource use.
►► Qualitative nested component—longitudinal interviews with a subsample of participants to understand
care provision in each setting and transitions between
settings.
Phase II will be conducted between 1 November 2016
and 30 April 2018, with follow-up ending on 31 May 2018.
The same variables and measurements as phase I will be
collected from clinicians. Additionally, patient/caregiver
participants will provide data on symptoms/concerns,
experience of care and their use of services, and will be
followed through all episodes of care from recruitment to
death or the end of this study. A post bereavement survey
will be conducted with caregivers where appropriate to
identify symptoms/concerns immediately prior to death
and support needs after death.
Guo P, et al. BMJ Open 2018;8:e020071. doi:10.1136/bmjopen-2017-020071
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Participants
Phase I: development phase
All adults (≥18 years) receiving specialist palliative care
newly admitted in 10 participating sites during the study
period (two sites providing hospital advisory services, one
providing community-based service only, six providing
hospice inpatient and community-based services, one
providing hospital advisory and community-based
services) were included, regardless of primary diagnosis.
We selected these sites with the aim of ensuring a representative sample in terms of population demographics
(age distribution, ethnicity, socioeconomic status and
rural/urban composition). Written informed consent
was taken by a qualified member of the research or clinical team. This phase included individuals with limited,
fluctuating, diminishing or lack of capacity, vital to
ensure that any casemix classification is applicable to
all palliative patients, not just those able to consent. It is
recognised that a high proportion of those have impaired
capacity, and these patients may need palliative care and
resources most.20–23 Therefore, if the clinician assessed
that the patient did not currently have the capacity to give
consent, assent was sought from an accompanying family
member, or failing that, a staff member to whom the
patient was known. Where a formally appointed power of
attorney existed, this took precedence.
Phase II: validation phase
All adults (≥18 years) receiving specialist palliative care
newly admitted from 14 sites during the study period
(participating sites in phase I, but extending to four additional sites to increase recruitment) will be eligible, regardless of primary diagnosis. Additional sites were accepted
if they could contribute to maintaining or extending
representativeness in terms of population demographics
(age distribution, ethnicity, socioeconomic status and
rural/urban composition). Written informed consent will
be sought from eligible patients (and their family caregivers) at the outset, including advance consent for study
follow-up if capacity is lost. This study is of minimal risk
with participants not exposed to undue harm.24
For both phase I and II, a list of study sites can be
obtained via https://www.kcl.ac.uk/nursing/departments/ c icelysaunders/ r esearch/ s tudies/ c - c hange/ c -
change.aspx.
Since transition of care is important for casemix, patient
participants who transfer between settings (and caregiver
participants) will be followed up. We will verbally confirm
continuing consent with each participant when making
such contact. If capacity of patient participants is lost, we
will seek advice from a personal consultee on whether the

patient should remain in the study to verify no change of
decisions has been expressed by the patient prior to loss of
capacity. On recruitment, participants will be asked if they
are willing to be interviewed at a later stage. To capture
variation in age, gender, diagnosis and geographical location, we will purposively select 20–25 patients and family
caregivers with at least two transitions of care for face-toface interviews. Each semistructured interview will last
40 min, but will be guided by each participant. In order
to provide information on how care transitions might be
better negotiated to improve outcomes and experiences,
the interviews will cover communication, coordination
of care, information/support needs, discharge planning
and experience of transitions.
Outcome
The outcome is cost of specialist palliative care (including
per diem cost, per phase cost, and total episode cost)
captured by: (1) staff activity matrix in both the development and validation phase, (2) the Palliative care Resource
Use Score (PRUS) in both phases and (3) Palliative Client
Services Receipt Inventory (Pall-CSRI) in validation phase
only.
Staff activity
At every contact, nurses, doctors and allied health professionals will record the time spent on face-to-face and
phone contacts, and patient-level administrative time per
shift using the staff activity matrix paper version (table 1).
Staff training and site feedback of activity data were
conducted regularly to improve and optimise data quality.
Palliative care Resource Use Score
PRUS is a questionnaire specifically designed to capture
palliative care resource use in a standardised way. It will
be collected by the staff at change of ‘phase of illness’25 26
and at the end of each episode by recording the following
information for the phase which has ended:
►► Level of professional input (eg, registered nurses,
specialist palliative nursing staff, palliative doctors
and social workers) and whether this met patient/
family needs.
►► Level of ‘out-of-hours’ services by professional
designation.
►► Equipment, high-cost drugs, diagnostic tests and
medical imaging. Within PRUS, the member of staff
is asked to indicate whether or not equipment, highcost oral/transdermal medications, injectable medications/interventions and medical imaging or tests
were received by the participant, from a list derived
from prior work to identify these options.

Table 1 Staff activity matrix (each box is completed in units of 5 min, from 0 up to 120 min)
Staff time (mins)

Patient

Family/carer

Professional (internal)

Professional (external)

Face-to-face/phone time
Administrative time

Guo P, et al. BMJ Open 2018;8:e020071. doi:10.1136/bmjopen-2017-020071
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►►

Any unmet needs which provide insight into any
gaps between needs and provision, as identified by
a member of staff.27–29 When completing PRUS, the
member of staff is asked to estimate retrospectively
if there were any unmet needs (yes/no) in the care
provided by healthcare assistants, registered nurses,
palliative medicine doctors and allied healthcare
professionals. This member of the staff is also asked
whether there were any unmet needs in out-of-hours
care, and whether the equipment provided met the
patient’s needs. If there were unmet needs identified
in any of these areas above, a free text field is provided
to specify these unmet needs.

Palliative Client Services Receipt Inventory
The Pall-CSRI is a patient/caregiver completed inventory
of palliative care services received, and adapted from those
used with palliative care populations.30 It takes approximately 20 min to complete and collect retrospective
information about the use of health/social care services,
medication, living situation, income, employment and
benefits, plus informal care. The Pall-CSRI will be collected
once every three months or at the end of each episode of
care, whichever is earlier in the validation phase.
In the development phase, only direct care costs will be
calculated but not productivity losses.31 Direct care cost
refers to all costs due to resource use that are completely
attributable to the use of a healthcare intervention or
illness, which can be split into direct medical costs (the
cost of a defined intervention and all follow-up costs for
other medication and healthcare interventions in ambulatory, inpatient, nursing care, home or other relevant
settings) and direct non-medical costs (eg, transportation
costs and additional paid caregiver time).32 In the validation phase, we will use the same health services costing
perspective as in the development phase, but informal
care costs are also considered to be in-scope and will
be analysed separately, hypothesising that informal care
costs are (1) greater in those with unmet needs, and (2)
greater in those with non-cancer conditions. The costs of
each resource item will be calculated by combining the
resource use data with appropriate unit cost obtained
from recognised sources including the annual compendium produced by the Personal Social Services Research
Unit,33 prices on the National Health Service (NHS)
supply chain website http://www.supplychain.nhs.uk,
British national formulary34 and NHS reference costs.35
The focus will be on staff time—the main resource in
palliative care documented in a variety of settings and
countries.36–38 We will attribute costs according to a standard costing methodology adopted from the current
NHS costing principles.39
Predictors (casemix criteria)
Proposed cost predictors can be categorised into three
groups: (1) predictors collected from clinicians, (2)
predictors collected from patients/family caregivers and
(3) model of care.
4

Table 2 Data from clinicians in both development phase
and validation phase
Type of data

Proposed cost predictors

Demographic data

Age
Gender
Postcode
Ethnicity
Marital status
Living circumstances
Need for interpreter
Setting of care

Clinical data

Primary diagnosis
Secondary diagnoses
Comorbidities

Episode start and end data

Episode start date
Episode end date
Endpoint of episode
(discharged or died).
Discharge destination, if
discharged

Key casemix

Phase of illness at start of
episode
Functional status (AKPS)
Dependency (Modified
Barthel Index)
Problem severity (IPOS staff
version)
Family/caregiver needs

AKPS, Australia-modified Karnofsky Performance Status; IPOS,
Integrated Palliative care Outcome Scale.

Predictors collected from clinicians
In both the development and validation phases, clinicians
will record demographic, clinical and episode start administrative data. Episode end data will be collected at the end of
each episode of care. Casemix data include phase of illness
(stable, unstable, deteriorating, dying), functional status
(measured by Australia-modified Karnofsky Performance
Status (AKPS)), dependency (Modified Barthel Index),
problem severity (Integrated Palliative care Outcome
Scale—IPOS staff version) and caregiver needs (table 2).
The measures are available directly from phase of illness
(www.pcoc.org.au), AKPS,40 Modified Barthel Index41
and IPOS (www.pos-pal.org), respectively. Phase of illness
will be assessed daily for people receiving inpatient care
and at each face-to-face contact basis for those receiving
community-based care. Other variables including AKPS,
Modified Barthel Index, IPOS staff (and caregiver needs
when feasible) will be collected at the start of episode, end
of episode and at change of phase of illness.
Predictors collected from patients and family caregivers
Variables (table 3) will be collected in the validation
phase from patients/caregivers using face-to-face/
Guo P, et al. BMJ Open 2018;8:e020071. doi:10.1136/bmjopen-2017-020071
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Table 3 Predictors collected from patients and family
caregivers in validation phase only
Data collection from
patients

Data collection from family
caregivers

IPOS patient version
Distress Thermometer

Basic demographic
information
Distress Thermometer

Views on Care

Two caregiver questions

SF-12v2*
Patient experiences of
integrated care

Zarit six items

*The measure could be completed by a family caregiver if the
patient is too unwell to complete.
SF -12v2, Short-Form Health Survey V.2.0.

telephone contacts and postal questionnaires according
to their preferences. IPOS patient version and Distress
Thermometer will be collected from patients at the start
of episode, at change of phase of illness and at the end
of episode. Views on Care and Short-Form Health Survey
V.2.0 (SF-12v2) will be collected at the start and end of
each episode of care. Selected questions capturing experiences of integrated care42 will be collected at the end of
episode only.
All caregiver- reported measures will be collected at the
start of episode, at change of phase of illness and at the
end of episode. Where phase length exceeds 4 weeks, data
collected from patients (and caregivers) will be captured
as a change of phase. If the patient is transferred to an
out-of-scope inpatient setting, we will follow up with the
patient when he or she gets home and retrospectively
collect minimum information about this episode of care.
If the patient is deceased, data such as SF-12v2 and
Pall-CSRI will be collected from the participating caregiver three months after death by postal questionnaire,
along with the bereavement support information and
contacts. The time between death and the postal questionnaire may influence caregivers’ willingness to share
their views; shorter periods possibly being too upsetting
to contemplate involvement.43 There is mixed evidence of
the best time to make contact with potential participants
for follow-back surveys44 45 and 3–4 months post bereavement is considered acceptable by bereaved families.30
Model of care
Models of care may be a stronger cost driver than patientlevel variables.13 14 16 Specialist palliative care services have
various configurations of staff, interventions and other
characteristics. Currently, there is no consistent way to
define models of palliative care. A separate, parallel study
will be conducted in which service-level data including
the numbers, disciplines and grading of staff, the nature/
duration of their involvement and use of volunteers will
be collected to comprehensively characterise different
models of palliative care provision in the participating
sites. With findings from this step, a new categorical
Guo P, et al. BMJ Open 2018;8:e020071. doi:10.1136/bmjopen-2017-020071

variable will be created representing ‘model of care’ to be
included in our analysis.
Sample size
In the development phase, based on standard recommendations for fitting multivariate models, a minimum of
50+8×m (where m is the number of predictors) is required
to test the hypothesis that the population multiple correlation equals zero with a power of 80%, alpha=5% and a
medium effect size for the regression analysis (R2=0.13).46
We estimated a sample size of 450 episodes per setting
(allowing for 25% incomplete episodes and up to 10%
of complete episodes being cost outliers with unusually
high or low costs). A total of 1350 patient episodes across
settings is needed.
In the validation phase, again a minimum of 50+8×m
(where m is the number of predictors) is required to
test the hypothesis that the population multiple correlation equals zero with a power of 80%, alpha=5% and a
medium effect size for the regression analysis (R2=0.13).46
In phase II, the number of predictors reflects the casemix
variables, and needs to be clinically relevant47 to ensure
a meaningful casemix classification. We expect the final
casemix classification to contain 5–8 casemix variables,
based on the Australian experience.13 We have estimated
that data from 114 (50+(8×8)) episodes of care per setting
(hospice, hospital, community) are needed. Assuming an
average of three episodes per participant15 in this longitudinal phase, this represents at least 38 participants per
setting. Allowing for 50% attrition, we estimate needing
a total of 228 participants, which will provide about 684
patient episodes. The sample size will be recalculated
and inflated using the design effect based on intraclass
correlation which will be estimated through interim analyses. A total of 300 participants across settings is needed,
including extra 25% participants allowing for intraclass
correlation.
Missing data and data handling
Data will be collected prospectively and recorded on an
electronic database. Any data transferred from the sites
to the central study database will be carried out under
the NHS Code of Practice on Confidentiality. Data will
be cleaned and cross-checked using a number of internal
checks (automated data validation on entry, independent cross-checking of a 5% sample of data from each
site and range checking across all data types) to track
errors and inconsistencies and amend where possible.
Checked data will be transferred to statistical software
(Stata SE V.12) for analysis. Missing value analysis will
be used to quantify missing values and understand the
reason for missing data: dropout of participants, errors
in data entry and missing with no identifiable reasons.
We will adopt multiple imputation technique based on
Markov Chain Monte Carlo techniques if the percentage
of observed missing values in independent variables
exceeds 10% provided values are missing at random,
and carry out sensitivity analysis for effects on casemix
5
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classification, predictive validity and misclassification,
where feasible.
Statistical analysis methods
We will use descriptive statistics including frequencies,
mean and SD, and median and interquartile ranges
as appropriate to describe the sample characteristics
and number and length of episodes of care. Trajectory
of outcomes and costs will be described, comparing
patterns in patients with cancer and without cancer, and
contrasting those with no unmet needs and those with
unmet needs. We will compare our data with existing
phase and episode data from the Australian Palliative
Care Outcome Collaboration.48 In the Australian classification, five casemix criteria (phase of illness, problem
severity, functional status and dependency, age, model
of care) were found to be most strongly predictive of
resource use. If our analyses demonstrate the same five
criteria as most predictive of resource use, the Australian
classification or a refinement of it will be adopted. If there
is disparity, then the data on individual casemix criteria
will be used to develop a new casemix classification, using

Figure 1

6

a recursive partitioning approach—specifically classification and regression trees49 50compared with multivariable
regression (figure 1).
Qualitative analysis methods
Audio-recordings will be transcribed verbatim and
checked for accuracy and entered into NVivo V.10. Data
will be independently coded and analysed by two members
of the research team. We will adopt a similar approach to
Pinnock,51 undertaking a thematic and narrative analysis
of interviews, exploring how perspectives evolve over time,
with detailed attention to patient and family perspectives
on experience of care in each setting and transitions,
including potential interventions (and hence cost levers
or other triggers) to influence changes in settings of care.
Model development
The distribution of casemix criteria (cost predictors) in
the participant population will be described based on
phase of illness, functional status and problem severity,
using parametric or non-parametric statistics, as appropriate. In order to reduce the number of cost predictors,

Data analysis flowchart. CART, classification and regression trees.
Guo P, et al. BMJ Open 2018;8:e020071. doi:10.1136/bmjopen-2017-020071
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we will initially use univariate analysis to explore the
association and strength of association between casemix
criteria and cost of the episode of care (quantifying cost
by per diem cost, per phase cost and total cost of episode).
We will use generalised linear model (multivariate regression model) to select variables that will then be applied in
a hierarchical manner to form a branching classification
in which each cost driver is incorporated only once.
We will select variables according to how much of the
predictive error (R2) each variable predicts and the related
P value. After each bootstrap iteration, we will rank the
variables according to these two criteria and remove the
weakest (non-significant) predictor. Variables shown in
tables 2 and 3 and the newly created categorical variable
representing ‘model of care’ will be initially entered into
the models and then non-significant predictors removed
at each iteration using a Bootstrap subsampling strategy.
We will create dummy variables to enable each level of
phase of illness and model of care (categorical variables)
to be assessed individually. Internal validation will be
conducted by using such methods as bootstrapping or

Figure 2

cross-validation to quantify any optimism in the predictive performance (calibration and discrimination) of the
developed classification.
Model specification
The casemix classification for each outcome across
three settings will be presented including all regression
coefficients and model intercept (figure 2). How to
use the classification will be explained. Understanding
how casemix variables predict cost of the episode of
care enables a robust casemix classification to be developed. But in order for casemix adjustment to occur,
there also needs to be a good understanding of how
the casemix variables impact on clinical outcomes, as
well as resource use. This casemix adjustment methodology is described in the recently published Department of Health document,52 which recommends that
significant casemix variables are identified, and that
the size of their relationship with clinical outcomes is
determined in advance.

Casemix classification specification.
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Multilevel modelling will be undertaken to ensure
that both of these steps will be delivered in this study by
determining (1) which casemix criteria are most strongly
associated with clinical outcomes, allowing for clustering
at the level of ‘participant’ (where episodes occur in the
same individual), at the level of ‘model of care’ (where
care is received according to similar models), and at the
level of ‘site’ (where care is delivered in a similar way
within site), and (2) which casemix criteria are the strongest cost predictor (including per diem cost, per phase
cost and total episode cost).
Model performance
The performance of the casemix classification will
be assessed in both the development and validation
data sets. Classification measures including sensitivity,
specificity, predictive values and net reclassification
improvement will be reported and cut points selected
a priori. We will primarily focus on discrimination
for the classification development phase, and assess
both discrimination and calibration for the validation phase.53 Discrimination of the classification will
be measured using the concordance statistic and CIs
(c-statistic).54 Calibration of the classification will be
measured using calibration plot and Hosmer-Lemeshow goodness-of-fit test.55
Development versus validation
Data will be collected from patients, caregivers and clinicians during the validation phase to compare patient-reported problem severity, that is, ‘felt’ need collected in
validation phase only (as measured by the patient-reported IPOS) and professional-reported problem severity,
that is, ‘normative’ need (as measured by the clinician-reported IPOS, phase of illness, AKPS), by reporting
correlation across levels of complexity and across conditions. We will assess how professional-reported measures
relate to patient-reported outcomes across different levels
of complexity (ie, in relation to casemix classes), in order
to determine optimal outcome measures and quality
indicators.
We will compare data on resource use from two sources:
(1) clinician-completed brief PRUS, and (2) patients and
family-completed CSRI, to better understand how the
PRUS maps to patients’ receipt of resources, and evaluate
which generic services are used across different providers,
regions and the context of different models of specialist
palliative care.
Ethical considerations
The study protocol and documents (eg, the participant information sheet, consent and declaration form)
have been approved by the NHS Health Research
Authority London—Camberwell St Giles Research Ethics
committee (15/LO/0887) for the development phase,
and NHS Health Research Authority London—Bromley
Research Ethics committee (16/LO/1021) for the validation phase.
8

All eligible participants are fully informed before
consent is sought by the local research team or
research nurses or project research team through the
information sheets and verbal explanation on the aims
and methods of the study and procedures that might
be involved. Participants can withdraw at any time up
to analysis of their data, without giving any reason. It
is possible that participants may become distressed or
raise issues during this study which raise concerns or
warrant a change in their medical management, but
we do not expect the questionnaires will themselves
cause distress so much as uncover pre-existing distress
which has not been acknowledged or recognised.
Should this be the case, then our distress protocol will
be followed. We anticipate distress will be infrequent,
given the general nature of the questionnaires. It is
likely that any distress will reflect advanced disease and
experiences of care, and not the questionnaires themselves. All of the study team members have completed
Good Clinical Practice training, and specific training
on addressing distress in palliative care.
Our existing Patient/Public Advisory Group and
extended Consumer Panel have been and will continue
to be consulted throughout the study to ensure that the
study is carried out in an ethical and respectful way, and
has the highest possible relevance and benefit to patients
and families. A Project Steering Committee meets once
every six months to monitor recruitment, review the
detailed progress of the study and make recommendations for overall direction and strategy.
Dissemination
This study will lead to patient benefit through improved
matching of resources to needs at individual patient-level
and will better enable the NHS to deliver high-quality,
patient-centred palliative care in last year of life. The
results of the study will be published in peer-reviewed
publications and will also be presented at national and
international conferences.
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